QIAGEN (QGEN) Stock Price, News & Analysis

Company Overview

QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials. The firm assay technologies make these biomolecules visible and ready for analysis. Its bioinformatics software and knowledge bases interpret data to report relevant, actionable insights. The company was founded by Detlev H. Riesner and Metin Colpan on April 29, 1996, and is headquartered in Venlo, the Netherlands.

Key Stats

• Today's Range: $49.11 to $49.49
• 50-Day Range: $46.54 to $51.80
• 52-Week Range: $37.63 to $51.88
• Volume: 695,538 shs
• Average Volume: 1.37 million shs
• Market Capitalization: $10.92 billion
• P/E Ratio: 29.03
• Dividend Yield: 0.51%
• Price Target: $49.69
• Consensus Rating: Hold

QIAGEN Stock Analysis - MarketRank™

QIAGEN scored higher than 75% of companies evaluated by MarketBeat, and ranked 253rd out of 937 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 1.1 / 5
• Analyst Rating: Hold

Consensus Rating

QIAGEN has received a consensus rating of Hold. The company's average rating score is 2.27, and is based on 3 buy ratings, 8 hold ratings, and no sell ratings.

Amount of Analyst Coverage

QIAGEN has only been the subject of 4 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.9 / 5
• Proj. Earnings Growth: 8.85%

Earnings Growth

Earnings for QIAGEN are expected to grow by 8.85% in the coming year, from $2.26 to $2.46 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of QIAGEN is 29.03, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 28.09.

Price to Earnings Ratio vs. Sector

The P/E ratio of QIAGEN is 29.03, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 30.46.

Price to Earnings Growth Ratio

QIAGEN has a PEG Ratio of 2.58. PEG Ratios above 1 indicate that a company could be overvalued.

Price to Book Value per Share Ratio

QIAGEN has a P/B Ratio of 3.12. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

3.07% of the float of QIAGEN has been sold short.

Short Interest Ratio / Days to Cover

QIAGEN has a short interest ratio ("days to cover") of 4.4.

Change versus previous month

Short interest in QIAGEN has recently increased by 4.76%, indicating that investor sentiment is decreasing.

Dividend

• Score: 1.7 / 5
• Dividend Strength: Weak

Dividend Yield

QIAGEN has a dividend yield of 0.51%, which is in the bottom 25% of all stocks that pay dividends.

Dividend Growth

QIAGEN does not have a long track record of dividend growth.

Dividend Coverage

The dividend payout ratio of QIAGEN is 14.79%. This payout ratio is at a healthy, sustainable level, below 75%.

Dividend Sustainability

Based on earnings estimates, QIAGEN will have a dividend payout ratio of 10.16% next year. This indicates that QIAGEN will be able to sustain or increase its dividend.

Sustainability and ESG

• Score: 4.5 / 5
• Environmental Score: -0.83

Percentage of Shares Shorted

3.07% of the float of QIAGEN has been sold short.

Short Interest Ratio / Days to Cover

QIAGEN has a short interest ratio ("days to cover") of 4.4.

Change versus previous month

Short interest in QIAGEN has recently increased by 4.76%, indicating that investor sentiment is decreasing.

News and Social Media

• Score: 3.4 / 5
• News Sentiment: 1.08

News Sentiment

QIAGEN has a news sentiment score of 1.08. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.52 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 13 news articles for QIAGEN this week, compared to 8 articles on an average week.

Search Interest

1 people have searched for QGEN on MarketBeat in the last 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, QIAGEN insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 9.00% of the stock of QIAGEN is held by insiders.

Percentage Held by Institutions

70.00% of the stock of QIAGEN is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

QGEN Stock Analysis - Frequently Asked Questions

How have QGEN shares performed this year?

QIAGEN's stock was trading at $43.2931 at the beginning of 2025. Since then, QGEN shares have increased by 13.5% and is now trading at $49.1340.

How were QIAGEN's earnings last quarter?

QIAGEN N.V. (NYSE:QGEN) issued its earnings results on Tuesday, August, 5th. The company reported $0.60 earnings per share for the quarter, hitting analysts' consensus estimates of $0.60. The firm's quarterly revenue was up 7.7% on a year-over-year basis.
Read the conference call transcript.

When did QIAGEN's stock split?

QIAGEN's stock split before market open on Wednesday, January 29th 2025.The 36-35 split was announced on Wednesday, January 22nd 2025. The newly issued shares were issued to shareholders after the market closes on Tuesday, January 28th 2025. An investor that had 100 shares of stock prior to the split would have 103 shares after the split.

Who are QIAGEN's major shareholders?

QIAGEN's top institutional investors include Massachusetts Financial Services Co. MA (11.03%), Groupama Asset Managment (6.75%), Amundi (1.85%) and Norges Bank (1.48%).

How do I buy shares of QIAGEN?

Shares of QGEN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of QIAGEN own?

Based on aggregate information from My MarketBeat watchlists, some other companies that QIAGEN investors own include NVIDIA (NVDA), Tesla (TSLA), Meta Platforms (META), Netflix (NFLX), Advanced Micro Devices (AMD), JPMorgan Chase & Co. (JPM) and PayPal (PYPL).

Company Calendar

• Ex-Dividend for 7/10 Dividend: 7/02/2025
• Record date for 7/10 Dividend: 7/03/2025
• Dividend Payable: 7/10/2025
• Last Earnings: 8/05/2025
• Today: 8/21/2025
• Next Earnings (Estimated): 11/05/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NYSE
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NYSE:QGEN
• CIK: 1015820
• Web: www.qiagen.com
• Phone: (177) 355-6600
• Fax: 31-77-355-6658
• Employees: 5,765
• Year Founded: N/A

Price Target and Rating

• Average Price Target for QIAGEN: $49.69
• High Price Target: $55.00
• Low Price Target: $43.00
• Potential Upside/Downside: +0.7%
• Consensus Rating: Hold
• Rating Score (0-4): 2.27
• Research Coverage: 11 Analysts

Profitability

• EPS (Trailing Twelve Months): $1.69
• Trailing P/E Ratio: 29.14
• Forward P/E Ratio: 21.84
• P/E Growth: 2.58
• Net Income: $83.59 million
• Net Margins: 18.30%
• Pretax Margin: 23.95%
• Return on Equity: 14.77%
• Return on Assets: 8.87%

Debt

• Debt-to-Equity Ratio: 0.25
• Current Ratio: 1.61
• Quick Ratio: 1.35

Sales & Book Value

• Annual Sales: $1.98 billion
• Price / Sales: 5.55
• Cash Flow: $3.22 per share
• Price / Cash Flow: 15.35
• Book Value: $15.77 per share
• Price / Book: 3.13

Miscellaneous

• Outstanding Shares: 222,290,000
• Free Float: 202,285,000
• Market Cap: $10.97 billion
• Optionable: Optionable
• Beta: 0.64